Navigation Links
Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph
Date:12/1/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Dec. 1 (HealthDay News) -- A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found.

When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said.

The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found.

''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid.

The study was funded by the drug maker Sanofi-Aventis -- which makes Taxotere, the brand name for docetaxel -- and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec. 2 issue of the New England Journal of Medicine.

To determine which women with breast cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors take into account a number of risk factors, such as the patient's age, tumor size and other characteristics.

For the new study, the researchers assigned 1,060 women with breast cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.

At the 77-month mark, almost 88 percent of the TAC women were alive and disease-free, compared to close to 82 percent of the women in the FAC group. Those in the TAC group had a 32 percent reduction in the risk of recurrence, the study authors said.

The reduced risk held true even after taking into account a number of high-risk factors, such as age, the women's menopausal status and tumor characteristics.

The differences in survival rates weren't significant from a statistical point of view -- 95.2 percent of TAC-treated women survived the follow-up, compared to 93.5 percent of the FAC-treated women.

However, adverse events from the drugs were more common with TAC -- 28 percent of patients, compared to 17 percent of the FAC patients.

''TAC is more toxic," Martin said, adding that ''all the toxicities were reversible." One common side effect was neutropenia, an abnormally low number of white blood cells. Fatigue was also a problem, the study found.

Another consideration: TAC chemotherapy is also substantially more expensive than FAC, Martin said, although he could not specify exactly how much more.

Even so, he said, "I think this study provides grounds for thinking of this regimen, particularly for those women with high-risk node-negative breast cancers."

Dr. Minetta Liu, director of translational breast cancer research at the Lombardi Comprehensive Cancer Center at Georgetown University, said the new study supports what many oncologists are already doing.

"Many oncologists are incorporating taxenes [such as docetaxel] in the adjuvant treatment for node-negative breast cancer," said Liu, who reviewed the study findings but was not involved with the research.

The ongoing challenge, Liu said, is deciding which women need the additional therapy. "This particular study's importance is that it illustrates there is a benefit in incorporating a taxene into the adjuvant treatment for some women with node-negative breast cancer."

More information

To learn more about breast cancer treatment, visit the U.S. National Cancer Institute.

SOURCES: Miguel Martin, M.D., Ph.D., professor of medical oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Minetta Liu, M.D., director of translational research, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; New England Journal of Medicine, Dec. 2, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New lung disease network to benefit patients and boost UK economy
3. Love Hormone May Boost Mens Memories of Mom -- Good or Bad
4. Love Hormone Boosts Memories of Mom -- Good or Bad, Study Finds
5. Behavior Disorders Boost Crash Risk for Teen Boys: Study
6. Poor Children Get Biggest Literacy Boost From Preschool
7. Higher Plavix Dose Wont Boost Outcomes After Stent Placement: Study
8. Scientists Find Way to Boost Good Cholesterol in Mice
9. Setting National Hospital Standards Could Boost Cardiac Care
10. Small assist device used in emergency case as twin, heart booster pumps for first time in US
11. Math Skills Boost Couples Financial Worth: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... August 18, 2017 , ... Alcovit, a lime-flavored beverage that rids the body ... with its product now available through Jet.com. , After 25 years of development, ... drink is designed to quickly detox the body thereby avoiding alcohol-induced hangovers. Whether you’re ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Dangerous Inheritance”: a mystery ... Diane Winters. Diane is from Southwest Nebraska where she was raised on a ... family. The story is fictional, but the friendships and mantra of ‘neighbors helping ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... marketers of high-quality anti-aging skincare solutions, recently announced the launch of ... products are an affordable, yet effective alternative to expensive plastic surgery or in-patient ...
(Date:8/18/2017)... ... 2017 , ... “Case #10-5411 Veterans Administration”: a personal account ... #10-5411 Veterans Administration” is the creation of published author, Carol Mulhern, single mother ... Mulhem started work at the Coatesville VAMC as a file clerk then later ...
(Date:8/17/2017)... ... August 17, 2017 , ... When Amy Cowperthwait ... nurse, she took with her a dream to make nursing education more relevant and ... ensuring communication skills were integrated into healthcare provider education. , “The human ...
Breaking Medicine News(10 mins):
(Date:8/7/2017)... Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global ... Directors has approved the payment of a quarterly cash dividend ... The cash dividend of $0.24 per ... to stockholders of record as of the close of business ... to approval of the Board of Directors and may be ...
(Date:8/4/2017)... 3, 2017  Agragen, LLC, a ... the biopharmaceutical, nutraceutical, and aquacultural feed sectors, announces ... lead drug candidates, AGR131.  This drug is designed ... the blood of patients suffering from inflammatory conditions ... disease. Biological ...
(Date:8/2/2017)... -- CaryRx, a next-generation full-service pharmacy, has announced the launch ... the Washington D.C. metropolitan area. CaryRx ... of medications through the convenience of its patient-friendly mobile app. ... one hour to any location in D.C. ... service to Washington D.C. ," says Areo ...
Breaking Medicine Technology: